Citadel Advisors’s Lexaria Bioscience Warrant LEXXW Stock Holding History

Citadel Advisors’s Portfolio LEXXW Stock Details LEXXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-13,241	Closed	-$5.96K	–	15086
2023 Q4	$5.96K	Sell	13,241 -6,636	-33%	-$2.2K	﹤0.01%	13387
2023 Q3	$4.17K	Sell	19,877 -5,294	-21%	-$1.27K	﹤0.01%	13511
2023 Q2	$5.54K	Buy	+25,171	New	+$8.69K	﹤0.01%	13493
2023 Q1	–	Sell	-10,496	Closed	-$4.2K	–	15139
2022 Q4	$4.2K	Buy	+10,496	New	+$5.26K	﹤0.01%	14121

Other funds holding LEXXW

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's LEXXW Position: Q1 2024 in Review

Citadel Advisors sold out of Lexaria Bioscience Warrant (LEXXW) in Q1 2024, closing a stake of 13,241 shares — an estimated $5.96K sold.

Citadel Advisors first reported a position in LEXXW in Q4 2022 and held it in 4 quarters. The position peaked at $5.96K in Q4 2023. 3 funds tracked by Wall St. Rank hold LEXXW as of Q1 2024.

Citadel Advisors reported no remaining Lexaria Bioscience Warrant position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 13,241 Lexaria Bioscience Warrant shares in Q1 2024, an estimated $5.96K.
Citadel Advisors first reported a position in Lexaria Bioscience Warrant in Q4 2022 and held it in 4 quarters.
Citadel Advisors's Lexaria Bioscience Warrant position peaked at $5.96K in Q4 2023.
3 funds tracked by Wall St. Rank held Lexaria Bioscience Warrant as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.